ALLO Allogene Therapeutics

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

ALLO stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


5 May 21
18 May 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 246.31M 246.31M 246.31M 246.31M 246.31M 246.31M
Cash burn (monthly) (positive/no burn) (positive/no burn) 11.07M 19.48M 16.44M 10.3M
Cash used (since last report) n/a n/a 17.57M 30.93M 26.1M 16.35M
Cash remaining n/a n/a 228.74M 215.39M 220.21M 229.96M
Runway (months of cash) n/a n/a 20.7 11.1 13.4 22.3

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
17 May 21 Veer Bhavnagri Common Stock Sell Dispose S No Yes 28.2951 5,000 141.48K 421,353
17 May 21 Veer Bhavnagri Common Stock Option exercise Aquire M No No 2.27 5,000 11.35K 426,353
17 May 21 Veer Bhavnagri Stock Option Common Stock Option exercise Dispose M No No 2.27 5,000 11.35K 137,300
15 Apr 21 Veer Bhavnagri Common Stock Sell Dispose S No Yes 32.6398 606 19.78K 421,353
15 Apr 21 Veer Bhavnagri Common Stock Sell Dispose S No Yes 32.0138 9,394 300.74K 421,959
15 Apr 21 Veer Bhavnagri Common Stock Option exercise Aquire M No No 2.27 10,000 22.7K 431,353
15 Apr 21 Veer Bhavnagri Stock Option Common Stock Option exercise Dispose M No No 2.27 10,000 22.7K 142,300
26 Mar 21 Schmidt Eric Thomas Common Stock Grant Aquire A No No 0 24,866 0 96,097
26 Mar 21 Schmidt Eric Thomas Stock Option Common Stock Grant Aquire A No No 33.78 92,365 3.12M 92,365
26 Mar 21 Amado Rafael Common Stock Grant Aquire A No No 0 24,866 0 134,901

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

70.9% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 164 160 +2.5%
Opened positions 25 27 -7.4%
Closed positions 21 40 -47.5%
Increased positions 70 56 +25.0%
Reduced positions 43 54 -20.4%
13F shares
Current Prev Q Change
Total value 2.53B 3.17B -20.0%
Total shares 100.37M 83.98M +19.5%
Total puts 126.6K 142.5K -11.2%
Total calls 106.5K 147.4K -27.7%
Total put/call ratio 1.2 1.0 +23.0%
Largest owners
Shares Value Change
TPG 18.72M $472.4M 0.0%
Capital Research Global Investors 12.64M $319.04M +0.2%
Seaview Trust 7.34M $185.28M NEW
Capital International Investors 7.13M $179.92M -1.9%
BLK Blackrock 6.47M $163.37M +2.5%
Vanguard 5.79M $146.05M +2.3%
Belldegrun Arie 3.71M $93.64M NEW
TROW T. Rowe Price 3.56M $89.85M -0.5%
STT State Street 3.37M $85.15M +31.6%
Alliancebernstein 2.59M $65.34M +33.9%
Largest transactions
Shares Bought/sold Change
Seaview Trust 7.34M +7.34M NEW
Belldegrun Arie 3.71M +3.71M NEW
Primecap Management 1.24M +1.24M NEW
Norges Bank 1.14M +1.14M NEW
Regents Of The University Of California 900.14K +900.14K NEW
STT State Street 3.37M +809.83K +31.6%
FMR 565.42K -732.43K -56.4%
Alliancebernstein 2.59M +654.71K +33.9%
GS Goldman Sachs 1.39M +548.32K +65.2%
Suvretta Capital Management 483.2K +483.2K NEW

Financial report summary

  • We have incurred net losses in every period since our inception and anticipate that we will incur substantial net losses in the future.*
  • Our engineered allogeneic T cell product candidates represent a novel approach to cancer treatment that creates significant challenges for us.
  • Gene-editing is a relatively new technology, and if we are unable to use this technology in our intended product candidates, our revenue opportunities will be materially limited.
  • The COVID-19 global pandemic is adversely impacting our business, including our preclinical studies and clinical trials.
  • We are heavily reliant on our partners for access to key gene editing technology for the manufacturing and development of our product candidates.
  • Our product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval.*
  • Our business is highly dependent on the success of our lead product candidates. If we are unable to advance clinical development, obtain approval of and successfully commercialize our lead product candidates for the treatment of patients in approved indications, our business would be significantly harmed.
  • Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.*
  • Our clinical trials may fail to demonstrate the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization.
  • Initial, interim and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • We may not be able to file INDs to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.*
  • We may encounter substantial delays in our clinical trials, or may not be able to conduct our trials on the timelines we expect.
  • Monitoring and managing toxicities in patients receiving our product candidates is challenging, which could adversely affect our ability to obtain regulatory approval and commercialize.
  • If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
  • The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.
  • Our development strategy relies on incorporating an anti-CD52 monoclonal antibody as part of the lymphodepletion preconditioning regimen prior to infusing allogeneic CAR T cell product candidates.*
  • We intend to operate our own cell therapy manufacturing facility, which will require significant resources and we may fail to successfully operate our facility, which could adversely affect our clinical trials and the commercial viability of our product candidates.*
  • We currently have no marketing and sales organization and as a company have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to generate product revenue.
  • A variety of risks associated with conducting research and clinical trials abroad and marketing our product candidates internationally could materially adversely affect our business.
  • We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.
  • We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.
  • We have grown rapidly and will need to continue to grow the size of our organization, and we may experience difficulties in managing this growth.*
  • We may form or seek additional strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.
  • We may not realize the benefits of acquired assets or other strategic transactions.
  • We will need substantial additional financing to develop our products and implement our operating plans. If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our product candidates.*
  • Our internal computer systems, or those used by our CROs, collaborators or other contractors or consultants, may fail or suffer security breaches.
  • Changes in funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely
  • manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.
  • Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.
  • Our relationships with customers, physicians, and third-party payors are subject, directly or indirectly, to federal, state, local and foreign healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we could face substantial penalties.*
  • European data collection is governed by restrictive regulations governing the use, processing, and cross-border transfer of personal information.
  • If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.
  • Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.*
  • We rely and will continue to rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.
  • We rely on third parties to manufacture our clinical product supplies, and we may have to rely on third parties to produce and process our product candidates, if approved.*
  • We rely on donors of T cells to manufacture our product candidates, and if we do not obtain an adequate supply of T cells from qualified donors, development of those product candidates may be adversely impacted.
  • Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.
  • If we or our third-party suppliers use hazardous, non-hazardous, biological or other materials in a manner that causes injury or violates applicable law, we may be liable for damages.
  • The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.
  • We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.
  • The regulatory landscape that will govern our product candidates is uncertain; regulations relating to more established gene therapy and cell therapy products are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval.
  • The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our CAR T cell product candidates.
  • We may be unable to obtain regulatory approval for ALLO-647 in a timely manner or at all, which could delay any approval or commercialization of our allogeneic T cell product candidates.
  • Regenerative Medicine Advanced Therapy designation may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.*
  • We plan to seek orphan drug designation for some or all of our product candidates across various indications, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.
  • Negative public opinion and increased regulatory scrutiny of genetic research and therapies involving gene editing may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.
  • Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community.
  • Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably.
  • The advancement of healthcare reform may negatively impact our ability to sell our product candidates, if approved, profitably.*
  • We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business.
  • If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market.
  • Confidentiality agreements with employees, Allogene Overland and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.
  • Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts and our ability to commercialize our product candidates.
  • We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.
  • We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.
  • The lives of our patents may not be sufficient to effectively protect our products and business.
  • We or our licensors may be subject to claims challenging the inventorship of our patents and other intellectual property.
  • Issued patents covering our product candidates could be found unpatentable, invalid or unenforceable if challenged in court or the USPTO.
  • Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.
  • We may not be able to protect our intellectual property rights throughout the world.
  • We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
  • The price of our stock has been and may continue to be volatile, and you could lose all or part of your investment.
  • We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.
  • Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.
  • Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.
  • Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.
  • If securities or industry analysts issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.
Management Discussion
  • Collaboration revenue was $38.3 million and zero for the three months ended March 31, 2021 and 2020, respectively. The increase of $38.3 million was due to collaboration revenue recognized pursuant to the license agreement with Allogene Overland.
  • Research and development expenses were $55.2 million and $42.0 million for the three months ended March 31, 2021 and 2020, respectively. The increase of $13.1 million was driven primarily by an increase in personnel related costs of $6.6 million, of which $1.3 million was increased stock-based compensation expense, an increase in external costs relating to the advancement of our product candidates of $5.1 million, and an increase in building rent and facilities costs of $1.7 million, offset by a decrease in travel related costs of $0.1 million due to the impact of the COVID-19 pandemic.
  • General and administrative expenses were $16.4 million and $15.6 million for the three months ended March 31, 2021 and 2020, respectively. The net increase of $0.7 million was primarily due to an increase in personnel related costs of $1.8 million, of which $1.3 million was increased stock-based compensation expense, offset by a decrease in business expenses and professional service fees of $0.7 million and a decrease in building rent and facilities costs of $0.3 million.
Content analysis
H.S. junior Avg
New words: alliance, analogy, appetite, attest, automating, Biden, Biopharm, carcinoma, carryover, ccRCC, constitutionality, constrain, constrained, cough, CY, diarrhea, distinct, dysfunction, enterprise, fashion, fatigue, formation, fratricide, furnish, hypophosphatemia, IGNITE, iv, JV, Korea, manual, migrated, mimic, misstatement, mutual, nausea, nonrefundable, Overland, overturning, potent, rash, ratio, reconsider, renal, SAP, signaling, Singapore, successor, Taiwan, toxicity, TRAVERSE, TurboCAR, unexplored, venture, vomiting, waiver, warehouse, withdrew
Removed: agent, animal, ASU, ByHeart, capitalized, capitalizing, chain, Clarifying, cloud, compound, computing, counterparty, deposit, efficient, elderly, formula, fourth, growing, guaranteed, hosting, infant, Interaction, interrupted, judgment, lab, leased, maintained, observed, oncology, onsite, outbreak, pediatric, precursor, prepare, presenting, relying, restatement, retrospective, Science, serve, Simplifying, statement, subleased, Subtopic, TSA, uncontrolled, unsure, worse, York


Chimeric Cytokine Receptors Comprising TGF Beta Binding Domains
4 Mar 21
Provided herein are chimeric cytokine receptors bearing a binding domain capable of binding a TGF-β ligand or a TGF-β receptor antibody.
Methods of Preparing T Cells for T Cell Therapy
4 Mar 21
Provided herein are methods for preparing T cells for T cell therapy comprising contacting a cell population at a predetermined cell density, with a concentration of an anti-CD3/CD28 nanomatrix and culturing the cells thereby producing a T cell population comprising an increased percentage of at least one T cell subtype.
Improved T Cell Compositions and Methods
23 Dec 20
The present invention provides compositions and methods that downregulate major histocompatibility class I molecule cell surface expression, and uses of such compositions and methods for improving the functional activities of isolated T cells (e.g., gene-modified antigen-specific T cells, such as chimeric antigen receptor T (CAR-T) cells).
Anti-talen Antibodies and Uses Thereof
16 Dec 20
The present disclosure provides, among other things, antibodies for detecting TALENs and/or FokI nucleases in a sample and methods of using the same.
Rituximab-resistant Chimeric Antigen Receptors and Uses Thereof
9 Dec 20
Provided herein are polynucleotides encoding chimeric antigen receptors (CARs) comprising a CD19 antigen binding domain that specifically binds to CD19 and is resistant to rituximab binding; and immune cells comprising these CD19-specific CARs, e.g., CAR-T cells.